MedPath

A prospective observational study of the efficacy and safety of CPT-11 based regimens (CPT-11+platinum analogues) for UGT1A1 genotype guided patients

Not Applicable
Conditions
Small cell lung cancer, non-small cell lung cancer, cervical cancer, ovarian cancer and gastric cancer (inoperable or recurrent)
Registration Number
JPRN-jRCT1080220914
Lead Sponsor
DAIICHI SANKYO COMPANY, LIMITED
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
1000
Inclusion Criteria

1. Small cell lung cancer, non-small cell lung cancer, cervical cancer, ovarian cancer and gastric cancer
2. Patients to receiving CPT-11 plus platinum anolaogues regimens
Age requirement none

Exclusion Criteria

1. Contraindications of CPT-11
2. ECOG PS 3-4

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Safety<br>None
Secondary Outcome Measures
NameTimeMethod
Efficacy<br>None
© Copyright 2025. All Rights Reserved by MedPath